NGEN.US NervGen Pharma Corp.
- Market cap
- USD 202M
- P/E
- -
- P/B
- 16.68x
- ROE
- -366.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NGEN.US undervalued?
Graham numberThe Graham number of NervGen Pharma Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NervGen Pharma Corp. fundamental analysis
No fundamental analysis for NervGen Pharma Corp. yet.
NervGen Pharma Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyot…
Full company profileNervGen Pharma Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NervGen Pharma Corp. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -19.7K | -39.3K | -39.7K | -43.0K | -114K | -145K | -83.7K | - | -57.0K |
| Operating Income | -12.0K | -1.35M | -10.1M | -11.2M | -12.9M | -22.8M | -17.8M | -24.9M | -25.1M | -40.4M |
| EBITDA | -12.0K | -1.33M | -9.99M | -11.2M | -12.8M | -19.9M | -22.2M | -23.9M | -5.65M | -28.4M |
| Net Income | -12.0K | -1.35M | -10.0M | -11.2M | -12.8M | -20.5M | -22.4M | -24.0M | -44.1M | -63.4M |
| EPS | 0.00 | -0.05 | -0.39 | -0.35 | -0.33 | -0.39 | -0.38 | -0.36 | -0.61 | -0.69 |
| Balance Sheet | ||||||||||
| Total Assets | - | 3.09M | 6.95M | 6.69M | 18.0M | 23.7M | 13.2M | 19.5M | 23.2M | 90.3M |
| Total Liabilities | - | 581K | 949K | 757K | 1.09M | 10.3M | 15.2M | 16.9M | 19.7M | 73.0M |
| Shareholders' Equity | - | 2.51M | 6.00M | 5.93M | 16.9M | 13.3M | -2.01M | 2.57M | 3.48M | 17.3M |
| Cash & Short-term Investments | - | 2.47M | 4.22M | 5.61M | 17.1M | 22.3M | 11.7M | 17.4M | 22.1M | 86.9M |
| Total Debt | - | - | - | - | - | 281K | 197K | 106K | 8.37K | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | - | -1.04M | -8.31M | -6.32M | -8.33M | -17.6M | -11.3M | -16.8M | -19.5M | -28.3M |
| Capital Expenditure | - | 0.00 | 0.00 | 3.43K | 2.77K | 20.9K | 5.63K | 0.00 | 0.00 | 8.36 |
| Free Cash Flow | - | -1.04M | -8.31M | -6.32M | -8.33M | -17.6M | -11.3M | -16.8M | -19.5M | -28.3M |
| Ratios | ||||||||||
| ROE | - | -54.0% | -167.2% | -188.9% | -75.7% | -153.9% | - | -931.7% | -1,268.9% | -366.3% |
| ROA | - | -43.9% | -144.3% | -167.6% | -71.1% | -86.8% | -169.1% | -123.2% | -190.1% | -70.2% |
| Debt to Equity | - | - | - | - | - | 0.02x | - | 0.04x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
NervGen Pharma Corp. dividends
NervGen Pharma Corp. has not paid dividends in the last 8 fiscal years.
Who owns NervGen Pharma Corp.
- Insiders 15.61%
- Institutions 11.92%
- Public & others 72.47%
- Shares outstanding 108M
- Free float 95.3M
Top funds holding NGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 67.4K | 0.06% | 0.00% | Aug 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 61.6K | 0.06% | 0.00% | Oct 2026 |
| iShares Neuroscience and Healthcare ETF | 8.26K | 0.01% | 0.00% | Oct 2026 |
Top institutions holding NGEN.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Empery Asset Management, LP | 4.00M | 3.72% | 0.00% | Jun 2026 |
| Rock Springs Capital Management LP | 1.21M | 1.12% | 0.00% | Jun 2026 |
| Dafna Capital Management LLC | 1.05M | 0.98% | 0.00% | Jun 2026 |
| Ghisallo Capital Management LLC | 1.00M | 0.93% | 0.00% | Jun 2026 |
| VALLEY FORGE INVESTMENT CONSULTANTS INC ADV | 834K | 0.78% | +8,241.56% | Sep 2026 |
| Armistice Capital, LLC | 678K | 0.63% | 0.00% | Jun 2026 |
| LMR Partners LLP | 600K | 0.56% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 436K | 0.41% | +117.59% | Jun 2026 |
| UBS Group AG | 380K | 0.35% | +517.27% | Jun 2026 |
| Stonepine Capital Management Llc | 272K | 0.25% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 271K | 0.25% | 0.00% | Jun 2026 |
| Woodline Partners LP | 251K | 0.23% | 0.00% | Jun 2026 |
| PFG Investments, LLC | 218K | 0.20% | +8.21% | Jun 2026 |
| Bank of America Corp | 186K | 0.17% | -7.20% | Jun 2026 |
| Royal Bank of Canada | 176K | 0.16% | +2.39% | Jun 2026 |
| Quadrature Capital Limited | 135K | 0.13% | 0.00% | Jun 2026 |
| Bank of Montreal | 78.4K | 0.07% | +24.63% | Jun 2026 |
| BMO Capital Markets Corp. | 78.4K | 0.07% | +24.63% | Jun 2026 |
| Integrated Wealth Concepts LLC | 74.2K | 0.07% | -14.51% | Jun 2026 |
| CapTrust Financial Advisors | 64.4K | 0.06% | +3.30% | Jun 2026 |
NervGen Pharma Corp. company profile
- Company name
- NervGen Pharma Corp.
- Ticker
- NGEN.US
- ISIN
- CA64082X2032
- Exchange
- USA Stocks
- Listed since
- Jan 8, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- 112-970 Burrard Street, Vancouver, BC, Canada, V6Z 2R4
- Phone
- 778 731 1711
- Website
- nervgen.com
About NervGen Pharma Corp.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
NervGen Pharma Corp. management
8- Dr. Adam H. Rogers M.D.President, CEO & Chairman
- Dr. Harold Martin Punnett D.M.D.Co-Founder & Independent Director
- Dr. Randall E. Kaye M.D.Chief Medical Advisor & Director · born 1962
- Dr. Keith A. Vendola M.B.A., M.D.Chief Financial Officer · born 1972
- Dr. Charles V. Olson D.Sc.Senior Vice President of Technical Operations · born 1957
- Ms. Shamim Ruff M.S.Chief Regulatory Affairs Officer · born 1960
- Ms. Christine McSherrySenior Vice President of Patient Advocacy & Clinical Affairs
- Ms. Marissa VolpeSVP of Clinical Development